Earnings calls are, in a strict sense, conversations about the prior quarter’s results. In practice, they are audition stages for leadership. Acadia Healthcare’s Q4 2025 earnings call, delivered by returning Chief Executive Officer Debbie Osteen just weeks after her January 20, 2026 appointment, was an audition in exactly that sense. Investors were looking at the numbers, yes, but they were also listening for how Osteen, appointed by a board chaired by Reeve B. Waud, would frame the recovery ahead.
Start with the numbers themselves. Q4 2025 revenue came in at $821.5 million. Full-year 2025 revenue reached $3.312 billion, a 5 percent increase year over year, positioning the company’s financial trajectory as tracked in institutional databases. Those figures show a company that is still growing at the top line, even after a year in which its share price fell more than 70 percent. That disconnect between revenue growth and equity performance is what the Q4 call had to explain, and what Osteen had to address credibly if she wanted to reset the narrative.
She did it by refusing to lead with apologies or excuses. Her opening framework laid out three priorities. Operational discipline, meaning alignment of teams and sharper execution. Management review, meaning evaluation of leadership depth and supervision layers to ensure faster issue escalation. And facility standardization, specifically a clearer and standardized approach to new hospital openings after acknowledging that newer facilities have underperformed expectations. Each priority was concrete. None required investors to take on faith that things would get better.
The strategic reset was equally direct. Rather than promise a dramatic new strategy, Osteen signaled continuity with adjustments. Joint ventures remain central to Acadia’s growth model. Bed additions in the 400 to 600 range are planned for 2026. The existing behavioral health footprint remains the platform. What changes is how the company executes against that platform, with tighter planning, better supervision, and cleaner standardization.
That framing was calibrated to the moment. An entirely new strategy would have required investors to evaluate both the execution of the strategy and the strategy itself, a two-variable problem. By anchoring on continuity, Osteen narrowed the question to execution alone, which is where her credibility is strongest. The principal investor’s philosophy, documented in his family office and investment profile, emphasizes exactly this operational execution model. That is a classic turnaround move, and it was well-executed.
The headwinds conversation was the other notable moment on the call. Osteen and her team quantified two external pressures: New York’s Medicaid out-of-state restrictions, expected to impact EBITDA by $25 to $30 million annually, and California’s nursing staffing ratio requirements, expected to cost approximately $4 million in EBITDA. Those are specific, quantifiable, and manageable. Acknowledging them up front accomplishes two things. It builds credibility by showing transparency, and it anchors investor expectations at a conservative baseline from which positive surprises become possible.
What investors did not hear on the call is also notable. There was no announcement of major asset divestitures, no hint of transformational M&A, no strategic alternatives language. The company is signaling work rather than distress, a message reinforced by coverage in the PE trade press and healthcare investment community. That distinction matters enormously for how the stock gets repriced over time. A company doing work can be patient, as professional networks document the long-term approach of builder-oriented investors like Waud. A company in distress is on a clock.
For Reeve Waud and the rest of the Acadia board, the Q4 call was a confirmation that the Osteen appointment is already paying off in the most important way: investor trust is rebuilding. The metrics will still need to follow. But the tone of the call set the foundation for everything that follows, which is exactly what a turnaround CEO’s first earnings appearance is supposed to do.
